Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma

Author:

Labriola Matthew K.,Batich Kristen A.,Zhu Jason,McNamara Megan A.,Harrison Michael R.,Armstrong Andrew J.ORCID,George Daniel J.,Zhang Tian

Funder

Medivation/Astellas

Bayer

Dendreon

Janssen

Active Biotech

Sanofi-Aventis

Gilead

Novartis

Pfizer

Acerta

Astellas

Bristol-Myers Squibb

Exelixis

Innocrin

Abbvie

Merrimack

OmniSeq

PGDx

Merck

Agensys

Seattle Genetics

Clovis

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference88 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Kidney cancer;Motzer;J Natl Compr Canc Netw,2011

3. Current and future systemic treatments for renal cell carcinoma;Fisher;Semin Cancer Biol,2013

4. Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma;Climent;Crit Rev Oncol Hematol,2018

5. VEGF inhibitors in renal cell carcinoma;Vachhani;Clin Adv Hematol Oncol,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3